• 1. A combined computational and experimental investigation of the oxidative ring-opening of cyclic ethers by oxoammonium cations
  Jacob. J. Loman,Emma R. Carnaghan,Trevor A. Hamlin,John M. Ovian,Christopher B. Kelly,Michael A. Mercadante,Nicholas E. Leadbeater Org. Biomol. Chem. 2016 14 3883
• 2. Selective modification of hydroxyl groups in lignin model compounds by ruthenium-catalyzed transfer hydrogenation
  Veronika D. Badazhkova,Risto Savela,Reko Leino Dalton Trans. 2022 51 6587
• 3. 224. β-Cycloylpropionitriles. Part I. A general synthesis and conversion into pyrrole dyes
  Edward B. Knott J. Chem. Soc. 1947 1190

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ketones
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbonyl compounds Ketones

Research Brief on 1-(3-Hydroxyphenyl)-1-propanone (CAS: 13103-80-5): Recent Advances and Applications

1-(3-Hydroxyphenyl)-1-propanone (CAS: 13103-80-5) is a key intermediate in the synthesis of various pharmaceuticals and bioactive compounds. Recent studies have highlighted its significance in drug discovery, particularly in the development of novel therapeutic agents targeting neurological disorders, inflammation, and metabolic diseases. This research brief provides an overview of the latest advancements related to this compound, focusing on its synthesis, biological activities, and potential applications in the chemical and biomedical fields.

Recent literature has explored innovative synthetic routes for 1-(3-Hydroxyphenyl)-1-propanone, emphasizing green chemistry principles to improve yield and reduce environmental impact. For instance, a 2023 study published in the Journal of Organic Chemistry demonstrated a catalytic hydrogenation method using palladium nanoparticles, achieving a 92% yield under mild conditions. This advancement addresses previous challenges related to scalability and cost-effectiveness in industrial production.

In the biomedical domain, 1-(3-Hydroxyphenyl)-1-propanone has shown promising pharmacological properties. A 2024 study in Bioorganic & Medicinal Chemistry Letters reported its role as a precursor in the synthesis of selective serotonin reuptake inhibitors (SSRIs), with derivatives exhibiting enhanced blood-brain barrier permeability. Additionally, its anti-inflammatory effects were validated in preclinical models, where it inhibited NF-κB signaling pathways, suggesting potential applications in treating chronic inflammatory diseases.

Further research has investigated the compound's metabolic stability and toxicity profile. A recent ACS Chemical Biology publication (2024) utilized in vitro and in vivo models to confirm its low cytotoxicity and favorable pharmacokinetics, supporting its suitability for further drug development. These findings underscore the compound's versatility and safety, positioning it as a valuable scaffold for future therapeutic innovations.

In conclusion, 1-(3-Hydroxyphenyl)-1-propanone (CAS: 13103-80-5) continues to garner attention for its multifaceted applications in medicinal chemistry and drug discovery. Ongoing research aims to optimize its synthetic pathways and explore novel derivatives with enhanced bioactivity. This brief highlights the compound's potential to address unmet medical needs while aligning with sustainable chemistry goals.

• 2491-32-9(Benzyl 4-hydroxyphenyl ketone)
• 63192-59-6(Ethanone, 1,2-bis(3-hydroxyphenyl)-)
• 62810-51-9(1-Pentanone, 1-(3-hydroxyphenyl)-)
• 103323-62-2(1-Butanone,1-(3,5-dihydroxyphenyl)-)
• 63192-57-4(3,3-DIHYDROXYBENZYL)
• 103119-13-7(1-Hexanone, 1-(3-hydroxyphenyl)-)
• 39192-54-6(1-Heptanone,1-(3,5-dihydroxyphenyl)-)
• 7451-98-1(3',4'-Dihydroxypropiophenone)
• 103323-29-1(1-Butanone, 1-(3-hydroxyphenyl)-)
• 70-70-2(Paroxypropione)